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Looking insight pathological processes, metallothioneins (MTs) are considered to be potential 
biomarkers for monitoring of a development of various types of malignant disease, such as 
cancer. The early identification of the MT biomarkers in biological tissues could be important 
tool for the estimation of appropriate clinical therapy. Therefore here we investigated the 
application of matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI 
MSI) together with immunohistochemical analyses (IHC) using MT-1/2 antibody for MT 
detection in formalin-fixed paraffin-embedded (FFPE) biopsy specimens of human skin. 
Principal component analyses revealed differences in the peptide/protein profiles separating 
healthy skin from the carcinoma specimens. Statistically significant ion peaks at m/z 6038, 
6300, 6676, and 7026 were more frequently detected in squamous cell carcinoma (SCC), 
basal cell carcinoma (BCC) and melanoma. Using IHC, we found that MT-1/2 was 
significantly higher in SCC and melanoma compared to healthy skin. Surprisingly, 
significantly low levels of MT-1/2 were found in BCC. On one side, the results indicate 
important role of MTs in melanoma occurrence and progression, as on the second side, there 
are hidden processes associated with MTs based on differences of the occurrence of the MS 
peaks, which could be associated with cycling of MTs isoforms.  
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Our expertise on protein spatial detection has evolved massively in last two decades 
especially due to techniques of mass spectrometry (MS), liquid chromatography (LC), 
immunohistochemistry, fractionation and multiplex assays [1-5]. Recently the proteomics 
technologies have been applied for the analysis of formalin-fixed, paraffin-embedded (FFPE) 
tissues [6]. Given the stability of FFPE tissues following fixation, large number of hospitals 
keep archives of these tissues together with patient diagnosis and outcome [1]. Methods of 
LC-MS/MS and 2D gel electrophoresis have been previously used for the identification of 
proteins from FFPE tissues [7, 8]. Furthermore, laser microdissection method (LM) and/or 
hydrogel-based method represent other proteomic approaches allowing for investigation of 
regions of interest within a larger tissue sections [9-11]. For the ordinary proteomic 
procedure, it is necessary to extract sufficient amount of tissue proteins to enable the analyses 
and protein identification. Regarding the above mentioned techniques of LC-MS/MS and 2D 
gel electrophoresis, none of them provides spatially registered data of the identified 
peptides/proteins [11]. Matrix assisted laser desorption/ionization mass spectrometry imaging 
(MALDI MSI) is able to analyse the spatial distribution of molecules at or near the surface of 
complex substrates and have been widely used for biomarker discovery, tumour classification 
and for determination of the origin of the primary tumour [12, 13]. In addition, MSI is 
compatible with histopathological assessment to define diagnosis and support the following 
therapeutic management [14, 15]. Immunohistochemistry (IHC) is a classical technique to 
study protein localization in tissues, as well as to confirm a protein's identity, and it is 
therefore complimentary to MALDI MSI studies [16].  
Due to its efficient ability to grow, invade and metastasise, malignant melanomas are 
considered as one of the most aggressive malignancies resulting in 80% of mortalities from 
skin cancer. The treatment of metastatic melanoma is still limited, regardless recent successes 
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of targeted therapies. For this reason understanding of disease progression, aiming at 
prediction of reaction to certain therapeutic treatments and identification of new therapeutic 
objectives is highly important [1].  
Metalloproteins represent diverse class of proteins with metal-binding sites providing a 
structural, regulatory and catalytic function(s). An interesting group of metalloproteins, 
known as markers of metal poisoning and potential markers of tumour diseases, comprises a 
family of metallothioneins (MTs) [17, 18]. In mammals, these low molecular mass cysteine 
rich proteins have four identified isoforms (MT-1 to MT-4) varying in expression and 
localization within individual tissues. Zn
2+ 
naturally binds to the mammalian MT at its α- and 
β-domains, nevertheless it may be substituted for another metal ion, which has a higher 
affinity for thiolate. It is not surprising that mammalian MTs are involved in detoxifying, 
maintaining homeostasis and storage of metal ions. Based on recent findings one may 
summarize that MTs have critical regulatory impact on apoptosis, immunomodulation, 
transcription regulation, proliferation and enzyme activation via the administration of Zn ions 
to proteins and regulation of the concentration of free Zn
2+
. Based on these facts, MTs are 
considered as important biomarkers for zinc status and metal exposure and importantly they 
might serve for the prognosis of certain tumour diseases. In addition, an increased content of 
heavy metals and MTs in tumour tissues can be connected to the increased invasiveness and 
metastasizing of a tumour cells [19-21]. All these findings indicate that MTs could have a 
great potential as diagnostic, prognostic and predictive cancer biomarkers, however, it 
remains hidden and undiscovered. To confirm such hypotheses, robust analytical techniques 
are needed. Detection and determination of metallothioneins are challenging tasks for 
analytical chemistry, when electrochemistry, immunochemistry, mass spectrometric and 
others are often used [22, 23], however, to the best of our knowledge, an approach for 
detection of these proteins spatially in a tissue is missing.  
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Therefore, a goal of the present study was to investigate the ability/suitability of MALDI MSI 
combined with IHC for detection of biological molecules in human skin tissues.  
 
2. Materials and Methods 
2.1. Characterization of the samples 
This study was approved by the Kenézy Gyula County Hospital Ethics Committee (Debrecen, 
Hungary), and informed consent was obtained from all subjects. Normal skin was derived 
from an 83-year-old female patient, who had a keratoacanthoma on her forearm. The resection 
margin free of any tumour cells was used for the study. Basal cell cancer (basalioma solidum 
et cysticum) was localized on the shoulder of a 61-year-old male patient. Superficially 
spreading malignant melanoma with Breslow tumour thickness 2.76 mm, Clark level III, 0-
2/hpf mitotic activity (pT3a) was removed from the thigh of a 47-year-old male patient. Grade 
2 cutaneous squamous cell cancer of an 86-year-old female patient was localized on her nose. 
Melanocytic nevus was removed from the chest of a 45-year-old female patient. 
 
2.2. Histology 
Formalin-fixed paraffin-embedded tissue blocks of various types of skin cancers were 
selected for MALDI MSI. Blocks of nevus and normal skin adjacent to a benign skin tumour 
were also included. All cases chosen for the study were diagnosed by a board-certified 
dermatopathologist. 4-µm sections were prepared from the tissue blocks and stained with 
haematoxylin-eosin for validation. Thereafter, 5-µm sections were cut and mounted onto ITO-





4-µm sections mounted on coated (or charged) glass slides were deparaffinized and 
rehydrated. Endogenous peroxidase was blocked in 1% (v/v) H2O2-methanol for 20 min at 
room temperature. Antigen retrieval was achieved by pressure-cooking the tissue samples in 
10 mM citrate buffer (pH = 6). After the slides were cooled (> 10 min), they were incubated 
with primary antibody for 1 hour at room temperature (MT-1/2 – clone E9, 1:50). For 
visualisation of the reaction, the horseradish peroxidase detection system and peroxide/DAB 
as substrates were used. The slides were counterstained with haematoxylin. 
 
2.4. MALDI MSI experiment 
The mass spectrometry imaging was performed on a MALDI-TOF/TOF mass spectrometer 
Bruker ultrafleXtreme (Bruker Daltonik GmbH, Bremen, DE). Broadband mass resolving 
power (RP) is up to 40,000 and the mass accuracy is 1ppm. In total 10 ITO glass slides 
containing 20 tissue sections were analysed. MALDI matrix was sprayed onto ITO glass 
slides containing deparaffinized skin samples applying ImagePrep
TM
 standard programs 
(Bruker Daltonik GmbH, Bremen, DE). Sinapinic acid (SA) and 2,5-dihydroxybenzoic acid 
(DHB) were used as MALDI matrices as follows: 10 mg mL
-1
 SA in acetonitrile/water (60:40, 
v/v) with 0.2% trifluoroacetic acid (TFA) and 30 mg mL
-1
 DHB in methanol/water (50:50, 
v/v) with 0.2% TFA. SA matrix was applied for the analyses of intact proteins, while DHB 
together with on-tissue trypsinization were used for peptide mapping. Prior analysis the slides 
were dried in vacuum desiccator for 15 min. Scanned images of tissue slices were loaded into 
FlexImaging 3.0 software (Bruker Daltonik GmbH, Bremen, DE) and MALDI adapter with 
two ITO glass slides was loaded into mass spectrometer. The position of MALDI adapter was 
taught according to white teaching marks on ITO glass slides. Regions of acquisition were 
highlighted by mouse pointer in FlexImaging and 50 μm raster width was chosen. The 
calibration was done externally using a peptide and protein standard mixture in the m/z range 
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0.5–20 kDa (Bruker Daltonik GmbH, Bremen, DE). The intensity of each scan, over the entire 
mass range acquired, was mapped on the tissue section image, allowing the visualization of 
the location of each m/z value detected. A laser power was set 5–10% above the threshold. 
MALDI MSI of proteins was performed in linear positive mode in the m/z range 1–20 kDa. 
MALDI MSI of tryptic peptides was performed in reflector positive mode in the m/z range 
0.5–5 kDa. 500 spectra were summed for each spot using the Random Walk raster pattern, 
with no evaluation criteria. The m/z images were generated and visualized using SCiLS Lab 
2014b software (SCiLS – Bruker Daltonik GmbH, Bremen, DE). Final corrections and 
preparations of the MALDI MSI images were carried out in GIMP 2.8 software. 
For on-tissue trypsinization, one ITO glass slide with each type of tissue was used – in total, 5 
ITO glass slides were used for trypsinization. Approximately, 300 μL of trypsin solution (20 
μg mL
-1
 in 40 mM ammonium bicarbonate, 0.1 mM HCl and 9% acetonitrile (v/v)) per one 
slide was applied by ImagePrep. Then, the slide was kept inside small box with humid 
atmosphere for 15 hours at 37 °C. Further, DBH matrix solution was applied. Prior MSI 
analysis the slide was dried in vacuum desiccator for 15 min. The LIFT cell was used for 
MS/MS analysis of detected peptides [24]. 
 
2.5. Statistical analysis of MSI data 
MSI data from FlexImaging were converted and uploaded into SCiLS Lab software that was 
used for pipeline pre-processing, segmentation and statistical analysis, mainly principal 
component analysis (PCA) with unit variance scaling, Anderson-Darling normality test and 






The representative protein (Fig. 1A) and peptide (Fig. 1B) profiles of the five types of human 
skin tissues were characterised using histology-directed MALDI MSI approach of specified 
regions of interest (ROIs). The mean protein peak intensities were considerably lower than the 
mean peak intensities of peptides as expressed in pseudo-gel views. To investigate the 
differences among the protein/peptide profiles, PCA of ROIs was applied (Fig. 2). The first 
two axes counted for 63.82% and 50.75% of the total variability for proteins and peptides, 
respectively. Protein profiles of healthy skin (HS) tissue and naevus pigmentosus (NP) were 
similar, while the carcinoma tissues of basal cell carcinoma (BCC), squamous cell carcinoma 
(SCC) and malignant melanoma (MM) were separated from the healthy specimens among the 
first axis (Fig. 2A). The overall protein profile similarities among the ROIs of the three types 
of skin cancer tissues resulted in overlapping of the BCC, SCC, and MM. The relative 
intensities of ion peaks at m/z 4376, 4879, 5154, 6038, 6300, 6676, 7026 and 14065 varied 
significantly and were responsible for the separation of healthy skin tissues from cancer 
tissues (Fig. 2B). Peptide profiles were able to differentiate SCC from the remaining tissue 
types along the PC1 axis, while HS, BCC and MM were partially separate from each other 
along the PC2 axis (Fig. 2C). Peptide m/z specific for MM were 1106 and 1461, for SCC 
tissue was characteristic the presence of m/z at 1199, 2182, and 2421. BCC and HS tissues 
were separated from each other by specific peptides at m/z 1586 and 616, respectively (Fig. 
2D).  
In protein profiles, the PCA and Kruskal-Wallis test indicated twelve statistically significant 
(p < 0.001) ion peaks (Supplementary Table 1) that were used for the formation of the MSI 
maps (Figs. 3, S1 and S2) and intensity box plots (Fig. 4s, S3 and S4). Primarily, we 
histologically examined the analysed samples (Fig. 3A), deparaffinised them (Fig. 3B) and 
detected the spatial distribution of four protein ion peaks at m/z 6038, 6300, 6676 and 7026 
(Fig. 3C). The MSI images together with the intensity box plots demonstrate that all four 
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selected m/z ion peaks are significantly (p < 0.001) more expressed in SCC, BCC and MM 
than in HS or NP regions (Figs. 4 A-D). The ion peak at m/z 6038 was tentatively identified 
as MT-1 based on the comparison of the MT human apo-forms from UniProtKB database and 
confirmed by the results of IHC analyses. For the peptide identification, the LIFT method was 
applied, nevertheless the low signal intensities did not allow for peptide characterisation. In 
comparison, immunohistochemical detection of MT-1/2 was performed on the same normal 
skin and skin cancer samples as we used for MALDI MSI (Fig. 5). The photos of the tissue 
slices are shown in Fig. 5A. The photomicrographs labelled by red rectangle are magnified in 
Fig. 5B and Fig. 5C, where histology and IHC staining are indicated, respectively. Intensive 
nuclear and cytoplasmic MT-1/2 presence was detected throughout the melanoma tissue. 
Highly proliferating cells at the invasive front of SCC also showed intensive staining, 
however, the expression of MT-1/2 seemed to disappear in more differentiated cancer cells. 
Basal cell cancer cells did not express MT-1/2. Moreover, the basal keratinocyte layer of 
epidermis was positively labelled with MT-1/2 antibody in both normal and tumour 
specimens (Fig. 5D). 
The MSI images of six remaining statistically significant m/z ions are shown in Fig. S1 and 
S2 together with intensity box plots (Figs. S3 and S4). SSC tissue was characteristic by 
higher abundance of in peaks at m/z 3376 and 3447, while m/z 4376, 4879 and 5154 were 
detected in higher levels in SSC, BCC and MM when comparison with NP and NS. Ion peaks 
at m/z 9323, 11422, and 14065 were overexpressed in MM and m/z 9323 was also 
significantly expressed in SCC tissue. 
 
4. Discussion 
The presented work aimed to establish an analytical methodology applying MALDI MSI 
together with IHC method for the detection of MT levels in biological tissues. In the present 
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study we have chosen the skin specimens since the skin is the larges organ of human body 
being intensively exposed to insults that might result in benign to lift-threating diseases. The 
progression of the disease is characterized by the specific changes on molecular level 
representing a unique peptide/protein signatures that can be exploited to classify and correlate 
clinically relevant information for disease treatment [25, 26]. Here we demonstrate that 
MALDI MSI technique together with IHC analyses is capable to successfully visualize spatial 
distribution of various proteins and peptides in FFPE tissues of human skin tumours and 
healthy skin. The novelty of the presented work relies on the combination of these two 
analytical techniques for possible application in clinical medicine. In analysing the cancer 
tissue by MALDI MSI, each of the peaks tentatively attributed to MTs can be monitored 
individually within single sample allowing for multiplex signature generation applied for 
improvement of skin cancer classification. Using suitable MSI statistical software, the 
significant mass peaks in the protein profiles were detected at m/z 6038, 6300, 6676 and 7026 
(p < 0.001). The occurrence of peak at m/z 6038 in tumour area was consistent with IHC 
staining for MT-1/2 in SCC, BCC and MM. IHC analyses using specific MT-1/2 antibody 
revealed elevated expression of MT-1/2 in SCC and MM. However, in BCC the MT-1/2 
expression was negative. From the analytical point of view, the analysis of homogenised, 
digested tissue applying LC-MS/MS combined with electrospray ionization (ESI) would 
allow for effective protein/peptide separation [27]. Nevertheless during the tissue 
homogenization the spatial information of protein location is lost. Therefore recently 
developed hydrogel-based method for spatial protein extraction from FFPE tissue might be 
the right choice to overcome the aforementioned problem [11]. Regardless of the numerous 
advantages provided by identification of peptides/proteins by LC-MS/MS, the method of 
MALDI MSI could not be replaced considering the biomolecules imaging without the 
labelling and creation of multiple species images from one initial experiment [28, 29]. Protein 
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delocalisation across tissue sections together with the decreased sensitivity caused by 
oversampling are the two topics associated with the type of high spatial resolution imaging 
used in this study [16]. Delocalisation has been addressed here by the separation of matrix 
coating from analyte extraction through a recrystallization process using the ImagePrep. 
Despite the fact that numerous advances have been made to elevate the MALDI MSI spatial 
resolution ability, this remains one of the main restrictions of the technique [30].  
The conditions used here for the MALDI MSI experiments applying the DHB and SA 
matrices resulted in elimination of the metal ion from the MT. In our experiment, the 
calculated masses of human MT apo-forms according to the UniProtKB database are 6120 Da 
for MT-1A, 6115 Da for MT-1B, 6014 Da for MT-1E, 6086 Da for MT-1F, 6141 Da for MT-
1G, 6039 Da for MT-1H, 6062 Da for MT-1L (1R), 6110 Da for MT-1K (1M), 6068 Da for 
MT-1X, 6042 Da for MT-2A, 6927 Da for MT-3 and 6509 Da for MT-4. In human skin, MTs 
were previously identified mainly by IHC analyses and/or molecular gene expression 
methods. Expression human skin, all major human MT isoforms (MT-1, MT-2, MT-3 and 
MT-4) have been found [31]. Due to a high sequence and structural similarity of MT-1 sub-
isoforms, their distinguishing on the protein level is complicated. Therefore, their expression 
is mostly evidenced on the mRNA level. This is however not fully consistent with the 
translated proteins mostly due to possible RNA silencing or turnover. Despite that, several 
studies have described MTs encoding mRNA as plausible biomarkers of pathophysiological 
states. For instance, active expression of MT1G, MT-1H and MT-2A genes was found in 
human skin fibroblasts after exposure to Cd
2+
[32], up-regulation of MT-1F, MT-1X, MT-1E 
and MT-2A genes was found as a consequence of exposure of human keratinocytes to 
nontoxic concentrations of Zn
2+
 [33] and expression of  MT-1A, MT-1G, MT-1F, MT-1X and 
MT-2A was found to be decreased in proliferating keloid fibroblasts compared to normal 
fibroblasts. Contrary to that, expression of MT-1A, MT-1E, MT-1F and MT-2A was found to 
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be increased in keloid keratinocytes compared to normal keratinocytes [34]. Noteworthy, no 
evidence on expression of MT-1B, MT-1L, MT-1M in normal skin was found. The 
keratinocytes in the basal layer of the epidermis constitutively express MT-1, whereas the 
spinous layer is characterised by MT-4 expression [35]. Low MT-3 protein expression has 
been demonstrated in normal skin epidermis [36, 37]. Aiming our attention at malignant 
processes, it has been described that changes in MTs levels might play a role in the 
conversion of a potentially malignant lesion to a malignant carcinoma. Significantly higher 
MT-1/2 and MT-3 expression was noted in actinic keratosis and cutaneous squamous cell 
cancer, as compared with normal skin epidermis, whereas very low levels of MT-3 expression 
were found in BCC [21, 36-38]. In superficial and nodular BCC a decreased/absent 
expression of MT-1/2 could be demonstrated, whereas an increased MT-1/2 expression was 
found in infiltrative type BCC [39, 40]. MT-1/2 over-expression has been found in cutaneous 
malignant melanomas in association with poor prognosis [41, 42]. Over-expression of cancer-
testis antigen 16 (CT16, PAGE5), a positive regulator of MT-2A has been demonstrated in 
melanoma metastasis [43]. Upregulation or moderate to intense expression of MT-3 was 
observed in melanoma and SCC [36, 37]. Nevertheless, MT-1E gene promoter 
hypermethylation causing decrease in MT1E transcription can be found in 1 of 17 (6%) of the 
benign naevi, in 16 of 43 (37%) primary melanoma tumours and in 6 of 13 (46%) melanoma 
metastases [44]. Higher incidence of promoter methylation of MT-1G was also demonstrated 
in melanomas compared with normal melanocytes and naevi [45]. 
Going deeper to the herein obtained data, MSI analyses together with IHC [46] suggest that 
one of the four ion peaks at m/z 6038 might belong to cysteine-rich metal-binding protein, 
MT, as IHC staining and MSI intensity was consistent with the tumour tissue of melanoma 
and the invasive front of SCC. On the other hand, very low levels of MT-1/2 expression were 
found by IHC in BCC that is consistent with the hypothesis that expression of MTs could be 
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also correlated with the epithelium stratification. Our data demonstrate that basal layer cells 
reveal lower expression of MTs compared to more differentiated cells of the suprabasal 
layers, which is in accordance of the results published by Pula et al. [36]. However, it is hard 
to conclude on the reason of a discrepancy in MT-1/2 levels analysed by IHC and MALDI 
MSI in BCC, when we hypothesize that MALDI MSI can identify all expressed sub-isoforms 
of MTs, which could not be detected using antibodies due to the non-existence of antibodies 
to all MTs isoforms. All these facts demonstrate the marked complexity of a role of MTs in 
skin biology. Despite the fact that an expression of mRNA encoding for MTs can be utilized 
as biomarker for diagnostic or prognostic purposes, only a proper quantitation and 
identification of translated protein can bring novel insights into the importance of MTs in skin 
cancer pathogenesis. 
Taking into consideration all of the previous discussion, it would seem that an alternative 
workflow may be proposed, whereby IHC, LC-MS, SALD ICP MS and MALDI MSI are 
used as complementary techniques [47, 48]. This more objective approach may notably 
decrease the timescale for biomarker discovery studies. Furthermore, we believe that the 
combination of different MS techniques together with IHC could lead to a description of 
differential expression of various sub-isoforms of MTs and substantially contribute to 
understanding of BCC pathogenesis. Moreover, recently applied technique immuno-MALDI 
(iMALDI) MS that uses anti-peptide antibodies for the specific enrichment of targeted 
analytes and on-target detection of the captured analytes [49], could be another solution for 
MT isoforms identification in FFPE tissues. We are keen to further investigate this 
challenging aspect employing LC-MS/MS technique together with MALDI MS and MSI to 





In conclusion, our results contributed to the basic knowledge on protein distribution in 
histologically specified regions in skin cancer tissues and would be used in further 
experiments aiming at elucidation of processes involved in skin carcinogenesis. We highlight 
the potential value of high-resolution images that allow for the evaluation of cutaneous, 
malignant melanoma and basal cell cancer proteomic details unreachable using other lower-
resolution investigative techniques. It is felt that the number of proteins identified and imaged 
could be improved if a strategy combining the analysis of tissue homogenates by LC- MS/MS 
(for identification purposes) together with SALD ICP MS and MALDI MSI for distribution 
analysis were employed. This will be the subject of further studies. 
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Captions for Figures 
Figure 1 
Pseudo-gel view for mean mass spectra from (A) protein ROIs, and (B) peptides ROIs in five 
different skin tissues. The triangles indicate m/z depicted in the PCA loading plots in Fig. 2. 
 
Figure 2 
(A) PCA scores plot of protein ROIs. (B) PCA loading plot of protein ROIs. (C) PCA scores 
plot of peptide ROIs. (D) PCA loadings plot of peptide ROIs. Green – normal skin, purple – 
naevus pigmentosus ROI, blue – squamous cell carcinoma ROI, red – basal cell carcinoma 
ROI, orange – malignant melanoma. Numbers in the loading plots indicate statistically 
significant m/z (p < 0.001).  
 
Figure 3 
Histological and MSI analysis of five different skin tissues, namely normal skin, naevus 
pigmentosus, squamous cell carcinoma (SCC), basal cell carcinoma (BCC), and malignant 
melanoma (MM). (A) Representative histological photomicrograph showing the particular 
tissue type. (B) Scanned pictures of the particular tissue type after the deparaffinization 
together with selected regions of interest (ROIs) used for MSI analysis. (C) Protein maps for 
ion peaks at m/z 6038, 6300, 6676 and 7026 generated as “[m/z] ± 10 Da”, scale bar = 1 cm. 
 
Figure 4 
Intensity box plots of selected protein m/z values (A) 6038, (B) 6300, (C) 6676 and (D) 7026 





Immunohistochemical (IHC), histological and MSI analysis of squamous cell carcinoma 
(SCC), basal cell carcinoma (BCC) and malignant melanoma (MM). (A) Representative 
photomicrograph showing increased (brown colour) or decreased MT-1/2 immunoreactivity 
in specific skin tissues. (B) Magnified histological photomicrograph showing the selected area 
(red rectangle) of the particular tissue type. (C) Magnified photomicrograph showing 
increased (brown colour) or decreased MT-1/2 immunoreactivity in specific skin tissues in the 
selected area (red rectangle). (D) Protein maps for ion peaks at m/z 6038, 6300, 6676 and 
7026 overexpressed in SSC, BCC and MM in the selected area (red rectangle), generated as 







Statistically significant ion peaks identified in protein profiles that account for the variation 
between five regions of interest (ROIs) in the studied skin specimens. 
 
Supplementary Captions for Figures 
Figure S1 
Protein maps for m/z 3376, 3447, 4376 and 4879 Da. All m/z images were generated as “[m/z] 
± 10 Da”. 
 
Figure S2 
Protein maps for m/z 5154, 9323, 11422 and 14065 Da. All m/z images were generated as 
“[m/z] ± 10 Da”. 
 
Figure S3 
Intensity box plots in all ROIs for m/z (A) 3376, (B) 3447, (C) 4376 and (D) 4879 Da. 
 
Figure S4 
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